235 related articles for article (PubMed ID: 16417966)
41. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
Wako K; Kawasaki T; Yamana K; Suzuki K; Jiang S; Umezu H; Nishiyama T; Takahashi K; Hamakubo T; Kodama T; Naito M
J Clin Pathol; 2008 Apr; 61(4):448-54. PubMed ID: 17720776
[TBL] [Abstract][Full Text] [Related]
42. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
Bydal P; Luu-The V; Labrie F; Poirier D
Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
[TBL] [Abstract][Full Text] [Related]
43. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
[TBL] [Abstract][Full Text] [Related]
44. Androgen metabolism in adipose tissue: recent advances.
Blouin K; Veilleux A; Luu-The V; Tchernof A
Mol Cell Endocrinol; 2009 Mar; 301(1-2):97-103. PubMed ID: 19022338
[TBL] [Abstract][Full Text] [Related]
45. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
[TBL] [Abstract][Full Text] [Related]
46. Prostaglandin F2alpha synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7.
Kabututu Z; Manin M; Pointud JC; Maruyama T; Nagata N; Lambert S; Lefrançois-Martinez AM; Martinez A; Urade Y
J Biochem; 2009 Feb; 145(2):161-8. PubMed ID: 19010934
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Himura R; Kawano S; Nagata Y; Kawai M; Ota A; Kudo Y; Yoshino Y; Fujimoto N; Miyamoto H; Endo S; Ikari A
Chem Biol Interact; 2024 Jan; 388():110840. PubMed ID: 38122923
[TBL] [Abstract][Full Text] [Related]
48. Expression of steroidogenic enzymes and sex-steroid receptors in human prostate.
Pelletier G
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):223-8. PubMed ID: 18471781
[TBL] [Abstract][Full Text] [Related]
49. Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer.
Pippione AC; Kovachka S; Vigato C; Bertarini L; Mannella I; Sainas S; Rolando B; Denasio E; Piercy-Mycock H; Romalho L; Salladini E; Adinolfi S; Zonari D; Peraldo-Neia C; Chiorino G; Passoni A; Mirza OA; Frydenvang K; Pors K; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
Eur J Med Chem; 2024 Mar; 268():116193. PubMed ID: 38364714
[TBL] [Abstract][Full Text] [Related]
50. Two pathways for prostaglandin F2 alpha synthesis by the primate periovulatory follicle.
Dozier BL; Watanabe K; Duffy DM
Reproduction; 2008 Jul; 136(1):53-63. PubMed ID: 18390687
[TBL] [Abstract][Full Text] [Related]
51. Oxytocin increases 5alpha-reductase activity of human prostate epithelial cells, but not stromal cells.
Assinder SJ
Prostate; 2008 Feb; 68(2):115-21. PubMed ID: 18008328
[TBL] [Abstract][Full Text] [Related]
52. Comparisons of (+/-)-benzo[a]pyrene-trans-7,8-dihydrodiol activation by human cytochrome P450 and aldo-keto reductase enzymes: effect of redox state and expression levels.
Quinn AM; Penning TM
Chem Res Toxicol; 2008 May; 21(5):1086-94. PubMed ID: 18402469
[TBL] [Abstract][Full Text] [Related]
53. Depot-specific prostaglandin synthesis in human adipose tissue: a novel possible mechanism of adipogenesis.
Quinkler M; Bujalska IJ; Tomlinson JW; Smith DM; Stewart PM
Gene; 2006 Oct; 380(2):137-43. PubMed ID: 16842938
[TBL] [Abstract][Full Text] [Related]
54. The roles of aldo-keto reductases in steroid hormone action.
Bauman DR; Steckelbroeck S; Penning TM
Drug News Perspect; 2004 Nov; 17(9):563-78. PubMed ID: 15645014
[TBL] [Abstract][Full Text] [Related]
55. 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer.
Barnard M; Quanson JL; Mostaghel E; Pretorius E; Snoep JL; Storbeck KH
J Steroid Biochem Mol Biol; 2018 Oct; 183():192-201. PubMed ID: 29936123
[TBL] [Abstract][Full Text] [Related]
56. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
57. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of solvent accessibility epitopes for different dehydrogenase inhibitors.
Ludwig C; Michiels PJ; Lodi A; Ride J; Bunce C; Günther UL
ChemMedChem; 2008 Sep; 3(9):1371-6. PubMed ID: 18576452
[TBL] [Abstract][Full Text] [Related]
59. Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin.
Lovering AL; Ride JP; Bunce CM; Desmond JC; Cummings SM; White SA
Cancer Res; 2004 Mar; 64(5):1802-10. PubMed ID: 14996743
[TBL] [Abstract][Full Text] [Related]
60. Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line.
Laplante Y; Poirier D
Steroids; 2008 Mar; 73(3):266-71. PubMed ID: 18082864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
